Recent News

• 03.26.2026 - IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
• 03.25.2026 - IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
• 03.24.2026 - IceCure Appoints Meir Peleg as Chief Financial Officer
• 03.17.2026 - IceCure Reports 2025 Full Year Financial & Operational Results
• 03.11.2026 - U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

Recent Filings

• 03.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.25.2026 - EX-99.1 EX-99.1
• 03.24.2026 - EFFECT Notice of Effectiveness
• 03.24.2026 - EX-99.1 EX-99.1
• 03.24.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.23.2026 - EFFECT Notice of Effectiveness
• 03.20.2026 - F-3/A Registration statement by foreign private issuers
• 03.20.2026 - POS AM Post-Effective amendments for registration statement
• 03.17.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.17.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]